Navigation Links
Older age doesn't affect survival after bone marrow transplant
Date:12/8/2008

SAN FRANCISCO ― Age alone should not determine whether an older patient with acute myeloid leukemia or myelodysplastic syndrome receives a blood stem cell transplant from a matched donor, researchers of the Center for International Blood and Marrow Transplant Research reported today at the 50th annual meeting of the American Society of Hematology.

Patients older than 65 do just as well as younger patients with transplants that are preceded by a milder chemotherapy regimen, according to an intensive analysis of every such transplant for AML or MDS conducted in North America between 1995-2005, said senior researcher Sergio Giralt, M.D., professor in The University of Texas M. D. Anderson Cancer Center Department of Stem Cell Transplantation and Cellular Therapy. The analysis also included international transplant data.

The retrospective study of 551 transplants for MDS and 565 for AML showed that age had no statistically significant impact on transplant-related mortality, relapse, leukemia-free survival or overall survival.

"These findings will be important in changing practice for the treatment of older patients," Giralt said. "We also hope the findings persuade the Centers for Medicaid and Medicare Services to recommend coverage of this therapy for MDS patients, as it does now for AML."

Findings will be presented at the meeting Monday morning by Dan McClune, D.O., of the University of Minnesota Masonic Cancer Center Department of Leukemia.

Matched donor, or allogenic, blood stem cell transplants originally were preceded with high-dose chemotherapy that destroyed the patient's blood supply before transplant. For patients over 65, this "myeloablative" chemotherapy was too toxic and therefore outcomes were poor.

Giralt and colleagues at M. D. Anderson pioneered the use of less-intensive chemotherapy that did not annihilate a patient's blood supply. This "non-myeloablative" preparation opened the door for older patients to receive the potentially curative transplants.

Still, some hesitancy has remained even for non-myeloablative transplants for older patients. Lack of Medicare coverage also reduces the number of patients who can receive the treatment, Giralt said.

The research project divided patients into four age groups: 40 to 54, 55-59, 60-64, and 65-plus. In addition to finding no statistically significant difference in survival across age groups, the researchers found no difference in acute or chronic graft-vs.-host disease.

The two most important prognostic variables were disease type and status of disease at transplant, which affected survival in the first year, and affected transplant-related mortality and relapse in the second year after transplant.

Giralt and Daniel Weisdorf, M.D., of the School of Medicine at Washington University, designed and proposed the research project to the Center for International Blood and Marrow Transplant Research. The CIBMTR is a joint effort of all stem cell transplant centers, which report their results to the center to facilitate research such as this study.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Most Newer Antipsychotics No Better Than Older Ones, Just Different
2. Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications
3. Vitamin K Slows Insulin Resistance in Older Men
4. Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto
5. 11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions
6. MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits
7. HLTH Corporation and WebMD to Webcast Annual Meetings of Stockholders
8. NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
9. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
10. Older Adults Who Exercise Boost Blood Flow in Brain
11. Guideline Urges HIV Tests for All Patients 13 and Older
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the launch ... mounts ever. , “Our goal was to develop a product from the ground ... we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The ...
(Date:2/10/2016)... ... ... The recreational use of marijuana has been legal in Colorado for over ... restrictions as to where they can smoke pot. , As Colorado’s website ... not be consumed openly or publicly.” , Given the momentum of the marijuana legalization ...
(Date:2/10/2016)... , ... February 09, 2016 , ... A new leadership ... Summer 2016. FHU President Joe Wiley made the announcement Monday night, Feb. 8, prior ... a 2003 graduate of FHU and the creator of GO! Camp, has been named ...
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. ... are delighted to welcome a new addition to their growing practice. Beginning this ... as a nurse practitioner performing cosmetic procedures including injectables, fillers and ...
(Date:2/10/2016)... , ... February 09, 2016 , ... ... concussion, yet the cause of injury may be one of many possible sources: ... PT Continuing Education Course , Mastering Rehab Solutions for the Complexities ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 ... and M 1 receptor selectivity   ... StaR® technology, which has entered clinical development as ... with dementia and schizophrenia.   --> ... technology, which has entered clinical development as a ...
(Date:2/9/2016)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... quarter ended December 31, 2015. ... Highlights , Revenue of $36.5 million compared to ... Domestic Radiation Measurement services revenues increased 2.8% year-over-year ...
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
Breaking Medicine Technology: